title: Nicotine potentiation of haloperidol-induced catalepsy: striatal mechanisms.
abstract: Nicotine potentiated the catalepsy produced by haloperidol. The excitotoxin quinolinic acid (QA) selectively destroys striatal neurons when injected directly into the striatum. Bilateral QA lesions of the rat striatum (150 nmol) significantly reduced the catalepsy produced by haloperidol as well as the ability of nicotine to potentiate haloperidol-induced catalepsy. A second experiment examined whether the ability of nicotine to potentiate haloperidol-induced catalepsy was associated with a potentiation of dopamine turnover following haloperidol. Nicotine alone produced a mild increase in dopamine turnover relative to saline treated controls while haloperidol produced a marked increase in dopamine turnover relative to saline- and nicotine-treated controls. However, the combined administration of haloperidol and nicotine did not further elevate dopamine turnover over that observed following haloperidol alone. The results indicated that: 1) nicotine could not potentiate haloperidol-induced catalepsy without an intact striatum and 2) the behavioral effect of nicotine and haloperidol cotreatment was not due to any change in dopamine turnover.
authors.affiliation: Department of Surgery, University of South Florida College of Medicine, Tampa 33612.
authors.forename: P R
authors.initials: PR
authors.lastname: Sanberg
authors.forename: D F
authors.initials: DF
authors.lastname: Emerich
authors.forename: M M
authors.initials: MM
authors.lastname: el-Etri
authors.forename: M T
authors.initials: MT
authors.lastname: Shipley
authors.forename: M D
authors.initials: MD
authors.lastname: Zanol
authors.forename: D W
authors.initials: DW
authors.lastname: Cahill
authors.forename: A B
authors.initials: AB
authors.lastname: Norman
mesh_terms: D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D002375:Catalepsy / Q000139:chemically induced* / Q000503:physiopathology; D002851:Chromatography, High Pressure Liquid; D003342:Corpus Striatum / Q000378:metabolism / Q000502:physiology*; D004298:Dopamine / Q000378:metabolism; D004357:Drug Synergism; D006220:Haloperidol; D006719:Homovanillic Acid / Q000378:metabolism; D008297:Male; D009538:Nicotine / Q000494:pharmacology*; D017378:Quinolinic Acid / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D015102:3,4-Dihydroxyphenylacetic Acid; D009538:Nicotine; D017378:Quinolinic Acid; D006220:Haloperidol; D004298:Dopamine; D006719:Homovanillic Acid